Primary refractory and early relapsed diffuse large B-cell lymphoma (PR/ER DLBCL)
Conditions
Interventions
Glofitamab Treatment Group:NA
Sponsors
Henan Cancer Hospital
Eligibility
Sex/Gender
All
Age
18 Years to 85 Years
Inclusion criteria
Inclusion criteria: 1. Age >=18 years at the initiation of treatment; 2. Diagnosis of diffuse large B-cell lymphoma (DLBCL); 3. Meeting the definition of primary refractory or early relapsed disease, defined as failure to achieve complete remission (CR) after four cycles of first-line induction therapy, or radiographically confirmed relapse within 12 months after achieving CR at the completion of induction therapy; 4. Patients who plan to initiate or have recently initiated treatment with glofitamab, either as monotherapy or in combination, after study initiation.
Exclusion criteria
Exclusion criteria: 1. Patients who are currently participating in or plan to participate in any interventional clinical trial; 2. Patients who are deemed by the investigator to be unsuitable for participation in this study for any other reason.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Objective Response Rate (ORR); | — |
Secondary
| Measure | Time frame |
|---|---|
| Adverse Events (AEs);All adverse events will be assessed and graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) version 5.0, including: All adverse events (AEs);Progression-Free Survival (PFS);Overall Survival (OS);Disease Control Rate (DCR);Minimal Residual Disease (MRD);Complete Response Rate (CR Rate); | — |
Countries
China
Contacts
Public ContactKeshu Zhou
Henan Cancer Hospital
Outcome results
None listed